External validation of the Oncotype DX breast cancer recurrence score nomogram and development and validation of a novel machine learning-based model to predict postoperative overall survival and guide adjuvant chemotherapy in ER positive, Her-2 negative breast cancer patients: a retrospective cohort study.

Journal: Frontiers in oncology
Published Date:

Abstract

BACKGROUND: This study aims to externally validate the performance of the Oncotype DX (ODX) breast cancer (BC) recurrence score nomogram in predicting adjuvant chemotherapy (ACT) for BC after surgery and subsequently develop a machine learning-based model to predict postoperative overall survival (OS) and guide ACT, demonstrating superior comprehensive performance.

Authors

  • Dongdong Wang
    Department of Radiology, Huashan Hospital Affiliated to Fudan University, 12 Wulumuqi Rd. Middle, Shanghai 200040, China.
  • Xinfeng Wang
    Institute for Global Public Policy, Fudan University, Shanghai 200433, China.
  • Xin Yang
    Department of Oral Maxillofacial-Head Neck Oncology, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China.

Keywords

No keywords available for this article.